Trial Watch: combination of tyrosine kinase inhibitors (TKIs) and immunotherapy

The past decades witnessed the clinical employment of targeted therapies including but not limited to tyrosine kinase inhibitors (TKIs) that restrain a broad variety of pro-tumorigenic signals. TKIs can be categorized into (i) agents that directly target cancer cells, (ii) normalize angiogenesis or...

Descripción completa

Detalles Bibliográficos
Autores principales: Petrazzuolo, Adriana, Maiuri, M. Chiara, Zitvogel, Laurence, Kroemer, Guido, Kepp, Oliver
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9154809/
https://www.ncbi.nlm.nih.gov/pubmed/35655707
http://dx.doi.org/10.1080/2162402X.2022.2077898

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9154809/
https://www.ncbi.nlm.nih.gov/pubmed/35655707
http://dx.doi.org/10.1080/2162402X.2022.2077898

Ejemplares similares